Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANJINTI vs POTELIGEO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
Adjuvant treatment of HER2-overexpressing breast cancer,Metastatic HER2-positive breast cancer (first-line in combination with chemotherapy),Neoadjuvant treatment of locally advanced or early stage HER2-positive breast cancer
Adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
Terminal elimination half-life: 28–38 days (mean ~32 days). Consistent with Ig G1 monoclonal antibody clearance; supports every-3-week dosing for sustained exposure
Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals.
Pertuzumab and trastuzumab are monoclonal antibodies degraded via catabolic pathways similar to endogenous Ig G, primarily through reticuloendothelial system; not metabolized by CYP450 enzymes. Hyaluronidase is degraded by hyaluronidases in tissues.
Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified.
Primarily hepatic metabolism; renal elimination of intact drug is minimal (<1%). Biliary/fecal excretion accounts for the majority of elimination (>90%)
POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces.
Non-specific binding to plasma proteins is negligible; >99% of trastuzumab circulates unbound (free). No significant binding to albumin or alpha-1-acid glycoprotein
Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody.
Mean Vd: 2.9–4.5 L/kg (approximately 200–300 L for a 70 kg patient), indicating distribution into tissues including lymph and interstitial space
Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces.
Not applicable for oral administration; only IV administration is approved. Bioavailability by IV route is 100%
Only intravenous administration; intravenous bioavailability is 100% by definition.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment recommended for Child-Pugh A or B. Safety and efficacy not established in Child-Pugh C; use only if benefit outweighs risk.
No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution.
Weight-based dosing: Same as adult schedule (mg/kg). Safety and efficacy established for children ≥2 years with HER2-overexpressing tumors; dosing based on body weight. Maximum area under the curve similar to adults.
Safety and effectiveness not established in pediatric patients.
No specific dose adjustment. Increased incidence of cardiac dysfunction in elderly; monitor left ventricular ejection fraction (LVEF) frequently. Dose modifications for toxicity same as adults.
No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline.
WARNING: CARDIOTOXICITY. KANJINTI can cause subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF. Evaluate cardiac function before and during treatment. Discontinue for clinically significant decline.
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
Cardiotoxicity (LVEF decline, heart failure),Infusion-related reactions (including anaphylaxis),Pulmonary toxicity (interstitial lung disease, pneumonitis),Embryo-fetal toxicity (oligohydramnios, fetal renal impairment),Exacerbation of chemotherapy-induced neutropenia
Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity.,Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected.,Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others.,Infections: Fatal infections occurred; monitor for infections and treat promptly.,Autoimmune hemolytic anemia: Fatal cases reported.,Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.,Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any component of KANJINTI
None
No known food interactions. Avoid grapefruit juice unless directed by healthcare provider.
No known food interactions. Grapefruit or other CYP inhibitors/inducers are not expected to affect mogamulizumab as it is a monoclonal antibody cleared via proteolysis. No dietary restrictions necessary.
KANJINTI (trastuzumab) is an Ig G1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when administered during the second and third trimesters. Exposure during organogenesis (first trimester) may also carry risks, but data are limited. Use is contraindicated in pregnancy.
POTELIGEO (mogamulizumab) is a monoclonal antibody. Ig G antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk.
Trastuzumab is excreted in human milk at low levels. The milk-to-plasma ratio is unknown. Due to the potential for adverse effects in the breastfeeding infant, advise women to discontinue breastfeeding during treatment and for 7 months after the last dose.
It is unknown whether mogamulizumab is excreted in human milk. Human Ig G is present in breast milk, but concentrations are generally low. The M/P ratio has not been determined. Due to the potential for serious adverse reactions in the breastfed infant (e.g., immunosuppression), women should not breastfeed during treatment and for at least 5 half-lives (approximately 5 weeks) after the last dose.
No specific dose adjustment is recommended in pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (increased plasma volume, altered renal clearance) may affect trastuzumab exposure, but no dose adjustment guidelines exist. Therapy should be discontinued if pregnancy occurs.
No pharmacokinetic studies in pregnancy. Dosing adjustments are not established; however, physiologic changes in pregnancy (e.g., increased plasma volume, altered clearance) may affect pharmacokinetics. Given the monoclonal antibody, no dose adjustment is recommended, but clinical monitoring for efficacy and toxicity should be considered. Use only if potential benefit justifies potential risk.
KANJINTI (trastuzumab-anns) is a biosimilar to trastuzumab. Administer as IV infusion; observe for infusion reactions. Do not mix with dextrose solutions. Confirm HER2 overexpression before use (IHC 3+ or FISH+). Monitor left ventricular ejection fraction (LVEF) at baseline and every 3 months. Contraindicated in patients with LVEF <50% or significant decline. Cardiotoxicity risk increases with anthracycline pre-treatment. Use with caution in pregnant women; may cause fetal harm.
Poteligeo (mogamulizumab) is a humanized anti-CCR4 monoclonal antibody used for adult T-cell leukemia-lymphoma (ATLL) and mycosis fungoides (MF)/Sézary syndrome (SS). It depletes CCR4-expressing T cells, including regulatory T cells (Tregs), which may exacerbate graft-versus-host disease (GVHD) after transplant. Monitor for infusion reactions and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). Dose reduction for creatinine clearance <30 m L/min is not established; avoid in severe renal impairment. Premedicate with antihistamines and acetaminophen. Live vaccines contraindicated during and after treatment.
Take only under prescription from a doctor.,Report any chest pain, shortness of breath, or swelling of ankles immediately.,Avoid pregnancy while on treatment; use effective contraception during and for 7 months after last dose.,Do not breastfeed during treatment and for 7 months after last dose.,Regular heart function tests (echocardiogram or MUGA) will be performed.,You may experience flu-like symptoms (fever, chills) after infusion; these are usually manageable.
Poteligeo can cause severe skin reactions; report any rash, blisters, or peeling skin immediately.,You may experience infusion reactions (fever, chills, nausea) during or after infusion; premedication will be given.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for at least 1 year after last dose.,Do not breastfeed while on Poteligeo and for at least 2 months after last dose.,Use effective birth control during treatment and for at least 3 months after last dose.,Notify your doctor if you have a history of organ transplant or are planning a transplant.,Poteligeo can lower your immune system; report signs of infection (fever, cough, sore throat).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANJINTI vs POTELIGEO, answered by our medical review team.
KANJINTI is a Monoclonal Antibody Antineoplastic that works by KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.. POTELIGEO is a Monoclonal Antibody Antineoplastic that works by Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANJINTI and POTELIGEO depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANJINTI is: 4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.. The standard adult dose of POTELIGEO is: 3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KANJINTI and POTELIGEO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KANJINTI is classified as Category C. KANJINTI (trastuzumab) is an IgG1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when ad. POTELIGEO is classified as Category C. POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on it. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.